Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
4 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2026 | $0 | -$17M | — | — | -$12M | — | $7M |
| 2025 | $0 | -$11M | — | — | -$8M | — | $9M |
| 2024 | $0 | -$15M | — | — | -$7M | — | $9M |
| 2023 | $0 | -$2M | — | — | -$2M | $0 | $865000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$3M | — | — | -$3M | — | $7M |
| Dec '25 | $0 | -$3M | — | — | -$3M | — | $10M |
| Sep '25 | $0 | -$7M | — | — | -$4M | — | $7M |
| Jun '25 | $0 | -$3M | — | — | -$3M | — | $9M |
| Mar '25 | $0 | -$3M | — | — | -$3M | — | $9M |
| Dec '24 | $0 | -$3M | — | — | -$2M | — | $12M |
| Sep '24 | $0 | -$3M | — | — | -$2M | — | $5M |
| Jun '24 | $0 | -$3M | — | — | -$2M | — | $7M |
| Mar '24 | $0 | -$15M | — | — | -$7M | — | $9M |
| Dec '23 | $0 | -$3M | — | — | -$3M | $1M | — |
| Sep '23 | $0 | -$6M | — | — | -$1M | — | — |
| Jun '23 | $0 | -$865000 | — | — | -$661000 | — | — |
| Mar '23 | — | -$657000 | — | — | -$620000 | $0 | $865000 |
| Dec '22 | — | -$544000 | — | — | — | — | — |
| Sep '22 | — | -$448000 | — | — | — | — | — |
| Jun '22 | — | -$341000 | — | — | — | — | — |
See the revenue and net-income charts above for Autonomix Medical, Inc.'s multi-year trend.
As of FY2026, Autonomix Medical, Inc. reported — of total debt against $7M of cash.
In FY2026, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.